Meridian Bioscience (NASDAQ: VIVO) was downgraded by Wedbush from a “neutral” rating to an “underperform” rating in a research note issued on Tuesday.
Meridian Bioscience, Inc. (Meridian) is a fully-integrated life science company. The Company is engaged in the developing, manufacturing, selling and distribution of diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics and Life Science. On July 20, 2010, the Company completed the acquisition of the Bioline group of companies (collectively the Bioline Group).
Shares of Meridian Bioscience traded down 0.52% during mid-day trading on Tuesday, hitting $17.20. Meridian Bioscience has a 52 week low of $14.81 and a 52 week high of $27.37. The stock’s 50-day moving average is $18.93 and its 200-day moving average is $18.48. The company has a market cap of $709.3 million and a P/E ratio of 26.20.